AUTHORS
Zihan Yang, MD, Anan Li, MD2, Yuan Huang3, Li-xin Wang4, Yu-xi Wang5, Jian Li, MD6
AFFILIATIONS
1 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 Intelligene Biosystems Co., Ltd., Qingdao, China
5 Intelligene Biosystems Co., Ltd., Qingdao, China
6 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
ABSTRACT
Background
Monoclonal immunoglobulin (M-protein) is a key marker of hematologic response in POEMS syndrome. However, conventional serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) may lack sensitivity for detecting low-level M-protein after treatment. Serum mass spectrometry (MS) enables sensitive and repeatable M-protein detection, but its clinical value for residual disease assessment in POEMS syndrome remains undefined. We evaluated the associations of MS-detected minimal residual disease (MS-MRD) with multidimensional response, progression-free survival (PFS), and dynamic disease evolution in patients who had achieved conventional hematologic complete response (CR).
Methods
This single-center retrospective study included patients who were diagnosed with POEMS syndrome and treated at Peking Union Medical College Hospital, achieved hematologic CR, and had stored serum available at 6, 12, 18, or 24 months after treatment. Hematologic CR was defined as negative serum and urine IFE. Samples obtained within 6 weeks of the 6-month landmark or within 8 weeks of the 12-, 18-, and 24-month landmarks were eligible; when multiple samples were available within a window, the sample closest to the landmark was selected. Serum MS-MRD was assessed using the iMS-IP Assay, an immunoenrichment-based matrix-assisted laser desorption/ionization time-of-flight MS platform. PFS was defined from sample collection to disease progression or death.
Results
Ninety patients contributed 128 samples: 30, 48, 30, and 20 at 6, 12, 18, and 24 months, respectively. Median age was 53 years, and 63 patients (70.0%) were male. Overall, 52 samples (40.6%) were MS-MRD negative and 76 (59.4%) were positive despite conventional hematologic CR. MS-MRD negativity rates were 40.0%, 27.1%, 56.7%, and 50.0% at 6, 12, 18, and 24 months, respectively. The VEGF CR rate was higher among MS-MRD-negative than MS-MRD-positive observations (29/30 [96.7%] vs 39/53 [73.6%]; P = 0.008). Neurologic response rates were similar (38/47 [80.9%] vs 45/58 [77.6%]; P = 0.811), and no significant differences were observed in evaluated organ responses.
A total of 108 samples were eligible for landmark PFS analyses. MS-MRD status at 6 months (12 negative vs 15 positive; P = 0.513) and 12 months (12 negative vs 30 positive; P = 0.292) did not significantly distinguish subsequent PFS. In contrast, MS-MRD-negative patients had superior PFS at the 18-month landmark (14 negative vs 12 positive; P < 0.001) and the 24-month landmark (7 negative vs 6 positive; P = 0.036). Median PFS was not reached in the MS-MRD-negative groups at either later landmark, compared with 20.5 and 29.0 months in the respective positive groups; no progression or death occurred among MS-MRD-negative patients at the 24-month landmark. During serial monitoring, 5 patients converted from MS-MRD negative to positive, of whom 4 subsequently developed hematologic, VEGF, or clinical progression.
Conclusions
Serum MS-MRD assessment may refine response evaluation beyond conventional hematologic CR in POEMS syndrome. Sustained MS-MRD negativity at later post-treatment time points may indicate deeper hematologic remission and more durable disease control, whereas conversion to MS-MRD positivity may signal an increased risk of relapse.
DISCLOSURES
Zihan Yang, MD: No relevant conflicts of interest to declare.